{"prompt": "['5.3.5.3', 'Adverse Events That Are Secondary to Other Events', 'In general, adverse events that are secondary to other events (e.g., cascade events or', 'clinical sequelae) should be identified by their primary cause, with the exception of severe or', 'serious secondary events. A medically significant secondary adverse event that is separated', 'in time from the initiating event should be recorded as an independent event on the Adverse', 'Event eCRF. For example:', 'If vomiting results in mild dehydration with no additional treatment in a healthy adult, only', 'vomiting should be reported on the eCRF', 'If vomiting results in severe dehydration, both events should be reported separately on', 'the eCRF', 'If a severe gastrointestinal hemorrhage leads to renal failure, both events should be', 'reported separately on the eCRF', 'If dizziness leads to a fall and consequent fracture, all three events should be reported', 'separately on the eCRF', 'If neutropenia is accompanied by an infection, both events should be reported separately', 'on the eCRF.', 'All adverse events should be recorded separately on the Adverse Event eCRF, if it is unclear', 'as to whether the events are associated.', '5.3.5.4', 'Persistent or Recurrent Adverse Events', 'A persistent adverse event is one that extends continuously, without resolution, between', 'patient evaluation timepoints. Such events should only be recorded once on the Adverse', 'Event eCRF. The initial severity (intensity or grade) of the event will be recorded at the time', 'the event is first reported. If a persistent adverse event becomes more severe, the most', 'extreme severity should also be recorded on the Adverse Event eCRF. If the event becomes', 'serious, it should be reported to the Sponsor immediately (i.e., no more than 24 hours after', 'learning that the event became serious; see Section 5.4.2 for reporting instructions). The', 'Adverse Event eCRF should be updated by changing the event from \"non-serious\" to', '\"serious,\" providing the date that the event became serious, and completing all data fields', 'related to serious adverse events.', 'A recurrent adverse event is one that resolves between patient evaluation timepoints and', 'subsequently recurs. Each recurrence of an adverse event should be recorded as a', 'separate event on the Adverse Event eCRF.', '5.3.5.5', 'Abnormal Laboratory Values', 'Not every laboratory abnormality qualifies as an adverse event. A laboratory test result must', 'be reported as an adverse event if it meets any of the following criteria:', 'Is accompanied by clinical symptoms', 'Results in a change in study treatment (e.g., dosage modification, treatment interruption,', 'or treatment discontinuation)', 'Results in a medical intervention (e.g., potassium supplementation for hypokalemia) or a', 'change in concomitant therapy', 'Emicizumab - F. Hoffmann-La Roche Ltd', '135 / Protocol MO39129, Version 3'][\"Is clinically significant in the investigator's judgment.\", \"It is the investigator's responsibility to review all laboratory findings. Medical and scientific\", 'judgment should be exercised in deciding whether an isolated laboratory abnormality should', 'be classified as an adverse event.', 'If a clinically significant laboratory abnormality is a sign of a disease or syndrome', '(e.g., alkaline phosphatase and bilirubin 5 X ULN associated with cholestasis), only the', 'diagnosis (i.e., cholestasis) should be recorded on the Adverse Event eCRF.', 'If a clinically significant laboratory abnormality is not a sign of a disease or syndrome, the', 'abnormality itself should be recorded on the Adverse Event eCRF, along with a descriptor', 'indicating whether the test result is above or below the normal range (e.g., \"elevated', 'potassium,\" as opposed to \"abnormal potassium\"). If the laboratory abnormality can be', 'characterized by a precise clinical term per standard definitions, the clinical term should be', 'recorded as the adverse event. For example, an elevated serum potassium level of 7.0', 'mEq/L should be recorded as \"hyperkalemia.\"', 'Observations of the same clinically significant laboratory abnormality from visit to visit should', 'only be recorded once on the Adverse Event eCRF (see Section 5.3.5.4 for details on', 'recording persistent adverse events).', '5.3.5.6', 'Abnormal Vital Sign Values', 'Not every vital sign abnormality qualifies as an adverse event. A vital sign result must be', 'reported as an adverse event if it meets any of the following criteria:', 'Is accompanied by clinical symptoms', 'Results in a change in study treatment (e.g., dosage modification, treatment interruption,', 'or treatment discontinuation)', 'Results in a medical intervention or a change in concomitant therapy', \"Is clinically significant in the investigator's judgment.\", \"It is the investigator's responsibility to review all vital sign findings. Medical and scientific\", 'judgment should be exercised in deciding whether an isolated vital sign abnormality should', 'be classified as an adverse event.', 'If a clinically significant vital sign abnormality is a sign of a disease or syndrome (e.g., high', 'blood pressure), only the diagnosis (i.e., hypertension) should be recorded on the Adverse', 'Event eCRF.', 'Observations of the same clinically significant vital sign abnormality from visit to visit should', 'only be recorded once on the Adverse Event eCRF (see Section 5.3.5.4 for details on', 'recording persistent adverse events).', '5.3.5.7', 'Abnormal Liver Function Tests', 'The finding of an elevated ALT or AST (> 3 X baseline value) in combination with either an', 'elevated total bilirubin (> 2 X ULN) or clinical jaundice in the absence of cholestasis or other', 'causes of hyperbilirubinemia is considered to be an indicator of severe liver injury (as', 'Emicizumab - F. Hoffmann-La Roche Ltd', '136 / Protocol MO39129, Version 3']\n\n###\n\n", "completion": "END"}